Skip to main content
. 2015 Jul 3;6(30):30317–30326. doi: 10.18632/oncotarget.4505

Figure 3. Subgroup survival analysis according to pretreatment EBV-DNA level.

Figure 3

In patients with positive pretreatment EBV-DNA level, negative post-treatment EBV-DNA level correlated with significantly superior PFS and OS A, B.